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Background
CAPS is an orphan auto-inflammatory disease, generally
diagnosed in childhood that requires life-long treatment.
Canakinumab, a fully human anti-IL-1b antibody, has
previously demonstrated rapid, complete and sustained
response in CAPS patients.
Aim
To compare dosing patterns of canakinumab in pedia-
tric and adult CAPS patients of a predominantly Wes-
tern population (WP) vs Japanese patients (JP).
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Figure 1 Step-wise up-titrations in patients (WP and Japanese) who did not achieve or remain in complete response
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Canakinumab s.c. 150 mg (if >40 kg) or 2 mg/kg (if ≤40
kg) was dosed every 8 weeks. Step-wise up-titrations in
dose were allowed in patients who did not achieve/
remain in complete response (CR, Figure 1).
Results
Median duration of treatment was 414 (29-687) days in
WP and 337 days (59-373 days) in JP. In the WP, CR
was achieved in 85/109 (78%) canakinumab-naive
patients. 127/141 (90%) evaluable patients remained in
CR throughout the study. 47/166 patients in WP and
11/19 patients in the Japanese study were pediatrics.
36.2% vs 81.8% (WP vs JP) of children received up-
titrated and/or more frequent doses. Higher median
doses were required in pediatric patients in the JP com-
pared with WP to control MWS and NOMID (Table 1).
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maximum permitted dose. None of those children
showed an unusual type or frequency of adverse events.
Conclusions
Increased doses of canakinumab were equally efficacious
in patients of a WP and Japanese population comprising
different CAPS phenotypes without evidence of a change
in AE profile. These data suggest that children and
patients with more severe CAPS phenotypes, irrespective
of ethnicity, require differential dosing.
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Table 1 Canakinumab doses by phenotypes
Phenotype (n=WP/
JP)
Wester population Japanese population
Adult
1 Mean/median (mg)
(N=136)
Pediatrics
2 Mean/mdeian (mg/kg)
(N=29)
Adult
1 Mean/median (mg)
(N=8)
Pediatrics
2 Mean/mdeian (mg/kg)
(N=11)
MWS (103/7) 200/150 5.5/4.0 225/150 6.0/6.0
NOMID (32/11) 299/150 5.8/4.0 300/225 5.5/6.0
FCAS (30/0) 189/150 2.7/2.0 - -
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